Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1

Conditions

Lymphoma 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Vomiting 1Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Philadelphia Chromosome 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Nausea 1Metastatic Neuroendocrine Prostate Cancer 1Medulloblastoma 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1Ependymoma 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma × Antiemetics × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
19 enrolled 18 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT01843868 2024-08-07

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Australasian Leukaemia and Lymphoma Group

Phase NA Withdrawn
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡